Document:

EX-10.20.1

 Exhibit 10.20.1 

THIS AMENDMENT AGREEMENT for BCT197 is dated October 19, 2018 (the Agreement) and made between: 

 

	(1)	 MEREO BIOPHARMA 1 LIMITED, a company incorporated and registered in England and Wales with company
number 09646998 whose registered office is at 4th floor, One Cavendish Place, London W1G 0QF (the Buyer); and 

 

	(2)	 NOVARTIS PHARMA AG, a company incorporated and registered in Switzerland whose registered office is
Postfach, 4002 Basel Switzerland (Novartis). 

 RECITALS 

 

	(A)	 On 28 July 2015, the Company executed an asset purchase agreement (the Purchase Agreement) to
acquire certain assets/rights of Novartis and its Affiliates related to the Compounds or Products (defined in the Purchase Agreement). 

  

	(B)	 The Buyer has entered into this Agreement in order to amend certain provisions of the Purchase Agreement.

  

	(C)	 In consideration of the foregoing premises and the mutual covenants and agreements contained herein, Buyer and,
on behalf of itself, and as applicable, its Affiliates, Novartis hereby agree as follows: 

  

	1.	 DEFINITIONS AND INTERPRETATIONS 

Unless otherwise stated, all words and phrases defined in the Purchase Agreement shall have the same meanings when used herein. 

 

	2.	 AMENDMENT 

  

	2.1	 Save as set out below, the Purchase Agreement shall remain in full force and effect. 

 

	2.2	 With effect from the date of this Agreement, the following amendments are made to the provisions of the
Purchase Agreement with the addition of the following new Section 5.10 entitled “Chemistry, Manufacturing and Controls Support” in Article V Covenants: 

“5.10 The Sellers shall: 
  

	 	(a)	 comply with GXP, including GLP and GMP, documentation in connection with the Development and Manufacture of the
Product; 

  

	 	(b)	 following reasonable prior notice, provide the Buyer with information, including books, records, files and
other information reasonably requested by the Buyer to respond to questions from any Governmental Authority, if such information is available to Seller and not previously transferred or made accessible to Buyer, including without limitation the FDA
and the European Medicines Agency, on the Development and Manufacture of the Product including the Manufacture of clinical batches of the Product by the Sellers for the purpose of regulatory filings to support clinical trial applications;

  

	 	(c)	 subject to Applicable Law, allow reasonable access by any Governmental Authority for the purpose of inspecting
the Sellers’ facilities responsible for the Manufacture of the Product and to permit representatives of the Buyer to be present and participate in any such inspection, upon reasonable prior written request and within reasonable hours.

	 	
If the main scope of such inspection is related to the Buyer’s product such inspection shall be at the cost of Buyer. Buyer shall furnish to Seller any reports by such Governmental Authority
to the extent relevant to the Seller as soon as reasonably practicable following receipt thereof by the Buyer. The parties acknowledge that the drug substance batches manufactured in support of Buyers clinical studies were released by Seller for use
in P2 studies only; 

  

	 	(d)	 provide additional information requested by any Governmental Authority and not previously transferred or made
accessible to the Buyer relating to the Development and Manufacture of the Product in support of any responses to questions from any Governmental Authority during review of any MAA or NDA for the Product, if such information is available to Seller;
The above support by Seller shall however be limited for the first two MAA or NDA for each molecule; 

  

	 	(e)	 render any assistance that Buyer may reasonably request pursuant to this Section 5.10 provided that Buyer
shall pay the Seller’s reasonable costs at the rate of Seller’s then current hourly rates, in the provision of such assistance following the receipt of the relevant invoice. 

 

	3.	 COUNTERPARTS 

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 
  

	4.	 GOVERNING LAW AND JURISDICTION 

This Agreement will be governed by, and construed in accordance with, the laws of the State of New York, without regard to the conflict of law
principles thereof. 
  

					
	 IN WITNESS WHEREOF, the Parties hereto have

duly executed this Agreement as of the date first
 above
written
	 		 	
			
	Buyer	 		 	
			
	MEREO BIOPHARMA 1 LIMITED	 		 	
			
	 acting by: Charles Sermon
  
	 	 }
 }
	 	
		 	}	 	 /s/ Charles Sermon

		 	}	 	Director
		 	}	 	

					
	Seller	 		 	
			
	NOVARTIS PHARMA AG	 	}	 	 /s/ Barbara Haeberlin

	a company incorporated in Switzerland acting by,	 	}	 	Name: Barbara Haeberlin
		 	}	 	Senior Head of Strategic Projects, TRD
	being a person who, in accordance with the laws of that territory, is acting under the authority of the company	 	 }
 }
	 	
		 		 	 /s/ Miki Nakamori

		 		 	Name: Miki NakamoriEX-10.20.2

 Exhibit 10.20.2 

ADDENDUM TO ASSET PURCHASE AGREEMENT 

This Addendum to Asset Purchase Agreement (“Addendum”) is entered into as of October 4, 2017 by and between Novartis Pharma AG, a Swiss company
(“Novartis”) and Mereo BioPharma 1 Limited, a private limited company incorporated in England and Wales, and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (collectively
“Mereo”). Hereinafter “Parties” shall mean Novartis and Mereo Biopharma l, and “Party” shall mean either Novartis or Mereo Biopharma l , as the context requires. 

WHEREAS the Parties entered into an asset purchase agreement on July 28, 2015 entitled “BCT Asset Purchase Agreement” (hereinafter “the
APA”); 
 WHEREAS subsequent to the execution of the APA the Parties have jointly filed patent applications identified as PCT/GB2017/052055, filed on
on 13 July 2017 claiming priority from the earlier British application No. 1612238.4 dated 14 July 2016 and PCT/GB2017/052056, claiming priority from British application No. 1612240.0 dated 14 July 2016 (hereinafter
“the Patent Applications”). 
 WHEREAS Novartis wishes to assign and Mereo Biopharma 1 wishes to receive all rights in the jointly conceived
inventive concepts. 
 NOW, THEREFORE, in consideration of the ongoing premises and the mutual covenants contained herein, Mereo Biopharma 1 and Novartis
hereby agree as follows: 
 l. Novartis hereby assigns all title rights and interest in the Patent Applications. The Parties acknowledge and agree that the
Patent Applications shall be considered Purchased IP as defined in the APA and as such all of the terms and conditions of the APA shall govern the rights and obligations of the Parties as they relate to the Patent Applications, 

2. Novartis acknowledges that it shall have no further rights to the Patent Applications unless specifically enumerated in the APA. 

3. This Agreement shall be governed by the laws of the State of New York, without regard to the conflict of law principles thereof. 

SIGNATURE PAGE TO FOLLOW 

 SIGNATURE PAGE 

 

	
	 /s/ Charles Sermon

	Mereo BioPharma I Limited Print Name:
	Print Name: CHARLES SERMON

  

	
	 /s/ Denise Scots-Knight

	 Mereo BioPharma I Limited
 Print Name: DENISE
SCOTS-KNIGHT

  

	
	 /s/ Isabelle Schubert Santana

	Novartis Pharma AG
	Print Name: ISABELLE SCHUBERT SANTANA

  

	
	 /s/ Ian Iiiscock

	Novartis Pharma AG
	Print Name: IAN IIISCOCK

  
 2EX-10.20.3

 Exhibit 10.20.3 

ADDENDUM TO ASSET PURCHASE AGREEMENT 
 This
Addendum to Asset Purchase Agreement (“Addendum”) is entered into as of April 12, 2016 by and between Novartis Pharma AG, a Swiss company (“Novartis”) and Mereo BioPharma 1 Limited, a private limited company incorporated in
England and Wales, and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (collectively ‘‘Mereo”). Hereinafter “Parties” shall mean Novartis and Mereo Biopharma 1, and
“Party” shall mean either Novartis or Mereo Biopharma l, as the context requires. 
 WHEREAS the Parties entered into an asset purchase agreement
on July 28, 2015 entitled “BCT Asset Purchase Agreement” (hereinafter “the APA”); 
 WHEREAS subsequent to the execution of the APA
the Parties have jointly filed patent applications at the UK Patent Office identified as PCT/GB2016/050635 and PCT/GB2016/050636 (hereinafter “the Patent Applications”). 

WHEREAS Novartis wishes to assign and Mereo Biopharma 1 wishes to receive all rights in the jointly conceived inventive concepts. 

NOW, THEREFORE, in consideration of the ongoing premises and the mutual covenants contained herein, Mereo Biopharma 1 and Novartis hereby agree as follows:

 1. The Parties acknowledge and agree that the Patent Applications shall be considered Purchased IP as defined in the APA and as such all of the terms and
conditions of the APA shall govern the rights and obligations of the Parties as they relate to the Patent Applications. 
 2. Novartis acknowledges that it
shall have no further rights to the Patent Applications unless specifically enumerated in the APA. 
 3. This Agreement shall be governed by the laws of the
State of New York, without regard to the conflict of law principles thereof. 
 SIGNATURE PAGE TO FOLLOW 

 SIGNATURE PAGE 
  

	
	 /s/ Denise Scots-Knight

	Mereo BioPharma I Limited
	Print Name: DENISE SCOTS KNIGHT
	CEO AND DIRECTOR
	
	 /s/ Charles Sermon

	Mereo BioPharma I Limited
	Print Name: C. SERMON
	                    DIRECTOR
	
	 /s/ Paul Fehlner

	Novartis Pharma AG
	 Print Name: Paul Fehlner

                     Head Intellectual Property
Pharma

	                     Novartis Pharma AG
	
	 /s/ Matt Owens

	Novartis Pharma AG
	Print Name: Matt Owens
	                     Global Head
Legal-
                     Strategic Partnership &
Digital Medicine

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]